查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613125

电脑辅助药物发现市场：按类型、治疗领域和最终用户划分 - 2025-2030 年全球预测

Computer-aided Drug Discovery Market by Type (Ligand-Based Drug Design, Sequence-Based Approaches, Structure-Based Drug Design), Therapeutic Area (Cardiovascular Disease, Diabetes, Neurology), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年电脑辅助药物发现市场规模为37.4亿美元，预计2024年将达到40.8亿美元，复合年增长率为9.71%，2030年将达到71.6亿美元。

电脑辅助药物发现 (CADD) 涉及使用计算方法和工具来帮助发现和优化新药物化合物的过程。这种创新方法对于减少传统药物开发的时间和成本至关重要，使其成为寻求效率的製药公司的关键必需品。 CADD 应用于药物开发的各个阶段，从标靶识别和验证到先导化合物化合物优化和临床前测试。最终用途主要来自製药和生物技术公司、学术和研究机构以及 CRO（委外研发机构）。该市场是由慢性病患病率不断上升、对精准医疗的日益重视以及人工智慧和机器学习技术的日益采用等因素所推动的。该领域的机会包括开发更复杂的演算法和平台，以提高药物发现过程的准确性和速度。公司可以透过投资人工智慧驱动的平台、整合巨量资料分析以及扩大与学术机构和科技公司的合作来利用这些进步。然而，高昂的初始成本、资料隐私问题以及对高品质资料来源的需求等挑战可能会阻碍成长。监管障碍和生物系统的复杂性等限制也可能阻碍准确的建模。随着市场随着技术进步而不断发展，公司专注于虚拟筛检、分子建模和资料整合等领域的创新至关重要。考虑到市场的本质，我们发现市场竞争格局非常激烈，既包括成熟的领导者，也包括创新的新进入者。获得市场占有率的最佳策略包括利用技术进步、建立战略伙伴关係以及强调开发支持个人化医疗方法的患者特异性模型，并最终与行业向精准医疗的发展保持一致。

主要市场统计
基准年[2023] 37.4亿美元
预测年份 [2024] 40.8亿美元
预测年份 [2030] 71.6亿美元
复合年增长率（%） 9.71%

市场动态：揭示快速发展的电脑辅助药物发现市场的关键市场洞察

供需的动态交互作用正在改变电脑辅助药物发现市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 製药和生物製药公司对药物开发活动的日益关注
    • 管理临床前研究期间产生的大量资料的需求日益增长
  • 市场限制因素
    • 实施电脑辅助药物发现解决方案的成本高昂
  • 市场机会
    • 增加电脑辅助药物发现解决方案的技术集成
    • 政府对创新技术采用的支持政策
  • 市场挑战
    • 与电脑辅助药物发现解决方案相关的各种替代技术的可用性

波特五力：驾驭电脑辅助药物发现市场的策略工具

波特的五力框架是了解电脑辅助药物发现市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：电脑辅助理解药物发现市场的外部影响

外部宏观环境因素在塑造电脑辅助药物发现市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 电脑辅助了解药物发现市场的竞争格局

对电脑辅助药物发现市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵电脑辅助供应商在药物发现市场的绩效评估

FPNV定位矩阵是评估电脑辅助药物发现市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

透过策略分析和电脑辅助建议，规划您在药物发现市场的成功之路

对于希望加强在全球市场的影响力的公司来说，药物发现市场的电脑辅助策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 製药和生物製药公司对药物开发活动的日益关注
      • 管理临床前研究过程中产生的大量资料的需求日益增长。
    • 抑制因素
      • 实施电脑辅助药物发现解决方案的成本高昂
    • 机会
      • 电脑辅助药物发现解决方案中技术的进一步集成
      • 支持引进创新技术的政府政策
    • 任务
      • 与电脑辅助药物发现解决方案相关的各种替代技术的可用性
  • 市场区隔分析
    • 类型：越来越多地使用基于配体的药物设计来开发可以预测新化合物活性的模型
    • 最终用户：电脑辅助药物发现在了解生物过程和识别潜在新药方面具有巨大潜力
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章电脑辅助药物发现市场：按类型

  • 基于配体的药物设计
  • 基于序列的方法
  • 基于结构的药物设计

第 7 章：按治疗领域分類的电脑辅助药物发现市场

  • 心血管疾病
  • 糖尿病
  • 神经病学
  • 肿瘤学
  • 呼吸系统疾病

第八章电脑辅助药物发现市场：按最终用户

  • 生技公司
  • 製药公司
  • 研究室

第 9 章美洲电脑辅助药物发现市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章按电脑辅助区域分類的亚太药物发现市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 电脑辅助的欧洲、中东和非洲药物发现市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • MilliporeSigma 宣布推出 AIDDISON：用于高效药物开发的开创性 SaaS 平台
    • 拜耳公司和 Google Cloud 合作透过量子化学推进新药发现
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Accelrys, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Chemical Computing Group Inc.
  • Dassault Systemes SE
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-5D693B46C018

The Computer-aided Drug Discovery Market was valued at USD 3.74 billion in 2023, expected to reach USD 4.08 billion in 2024, and is projected to grow at a CAGR of 9.71%, to USD 7.16 billion by 2030.

Computer-aided Drug Discovery (CADD) involves the use of computational methods and tools to aid in the process of discovering and optimizing new pharmaceutical compounds. This innovative approach is essential in reducing the time and cost associated with traditional drug development, making it a significant necessity for pharmaceutical companies striving for efficiency. CADD is applied throughout various stages of drug development, from target identification and validation to lead optimization and preclinical testing. The end-use scope primarily spans pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs). The market is driven by factors such as the increasing prevalence of chronic diseases, a growing emphasis on precision medicine, and the rising adoption of AI and machine learning technologies. Opportunities in this field include the development of more sophisticated algorithms and platforms that enhance the accuracy and speed of drug discovery processes. Companies can capitalize on these advancements by investing in AI-driven platforms, integrating big data analytics, and expanding collaborations with academic institutions and tech firms. However, challenges such as high initial costs, data privacy concerns, and the need for high-quality data sources can hinder growth. Limitations also include regulatory hurdles and the complexity of biological systems that may impede accurate modeling. The market is continuously evolving with technological advancements, making it crucial for businesses to focus on innovation in areas like virtual screening, molecular modeling, and data integration. Insights into the market's nature suggest a strong competitive landscape with both established leaders and innovative newcomers. The best strategies for capturing market share involve leveraging technological advancements, forging strategic partnerships, and emphasizing the development of patient-specific models to support personalized medicine approaches, ultimately aligning with the industry's trend towards precision therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.74 billion
Estimated Year [2024] USD 4.08 billion
Forecast Year [2030] USD 7.16 billion
CAGR (%) 9.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Computer-aided Drug Discovery Market

The Computer-aided Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
    • Increasing need to manage the large data generated during preclinical studies
  • Market Restraints
    • High cost of implementation of computer-aided drug discovery solutions
  • Market Opportunities
    • Rising integration of technologies in computer-aided drug discovery solutions
    • Supportive government policies for the adoption of innovative technologies
  • Market Challenges
    • Availability of wide alternative technologies associated with computer-aided drug discovery solutions

Porter's Five Forces: A Strategic Tool for Navigating the Computer-aided Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Computer-aided Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Computer-aided Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Computer-aided Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Computer-aided Drug Discovery Market

A detailed market share analysis in the Computer-aided Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Computer-aided Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Computer-aided Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Computer-aided Drug Discovery Market

A strategic analysis of the Computer-aided Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Computer-aided Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accelrys, Inc., AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Chemical Computing Group Inc., Dassault Systemes SE, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Schrodinger, Inc., Simulations Plus, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Computer-aided Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ligand-Based Drug Design, Sequence-Based Approaches, and Structure-Based Drug Design.
  • Based on Therapeutic Area, market is studied across Cardiovascular Disease, Diabetes, Neurology, Oncology, and Respiratory Disease.
  • Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
      • 5.1.1.2. Increasing need to manage the large data generated during preclinical studies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of implementation of computer-aided drug discovery solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising integration of technologies in computer-aided drug discovery solutions
      • 5.1.3.2. Supportive government policies for the adoption of innovative technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of wide alternative technologies associated with computer-aided drug discovery solutions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of ligand-based drug design to develop a model that can predict the activity of new compounds
    • 5.2.2. End User: High potential of computer-aided drug discovery to understand biological processes and identify potential new drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Computer-aided Drug Discovery Market, by Type

  • 6.1. Introduction
  • 6.2. Ligand-Based Drug Design
  • 6.3. Sequence-Based Approaches
  • 6.4. Structure-Based Drug Design

7. Computer-aided Drug Discovery Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Diabetes
  • 7.4. Neurology
  • 7.5. Oncology
  • 7.6. Respiratory Disease

8. Computer-aided Drug Discovery Market, by End User

  • 8.1. Introduction
  • 8.2. Biotechnology Companies
  • 8.3. Pharmaceutical Companies
  • 8.4. Research Laboratories

9. Americas Computer-aided Drug Discovery Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Computer-aided Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Computer-aided Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. MilliporeSigma Introduces AIDDISON: A Pioneering SaaS Platform for Streamlined Drug Development
    • 12.3.2. Bayer AG and Google Cloud Partner to Advance Drug Discovery Through Quantum Chemistry
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Accelrys, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Chemical Computing Group Inc.
  • 8. Dassault Systemes SE
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Regeneron Pharmaceuticals, Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Schrodinger, Inc.
  • 19. Simulations Plus, Inc.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMPUTER-AIDED DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE-BASED APPROACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023